

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived		
	Mouse CD47 (Gln19-Pro158) Accession # NP_034711	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus

N-terminal Sequence Analysis Gln19 predicted, no results obtained, sequencing might be blocked

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 42.3 kDa (monomer)

SPECIFICATIONS

SDS-PAGE 60-70 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
When Recombinant Mouse SIRPα/CD172a Fc Chimera (Catalog # 7154-SA) is coated at 2 µg/mL, Recombinant Mouse CD47 Fc Chimera binds with an apparent K_d <0.6 nM.
Also measured by its ability to antagonize mouse red blood cell adhesion to immobilized Recombinant Mouse SIRPα/CD172a Fc Chimera (Catalog # 7154-SA). The ED₅₀ for this effect is 2.0-8.0 µg/mL.
Optimal dilutions should be determined by each laboratory for each application.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 200 µg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

CD47, also known as Integrin-Associated Protein (IAP) and OA3, is a 40-60 kDa variably glycosylated atypical member of the immunoglobulin superfamily (1, 2). Mouse CD47 is an integral membrane protein that consists of a 122 amino acid (aa) extracellular domain (ECD) with a single Ig-like domain, five membrane-spanning regions with short intervening loops, and a 16 aa C-terminal cytoplasmic tail (3). Alternate splicing of mouse CD47 generates an additional isoform with an insertion of 21 aa following the Ig-like domain (3). Within the N-terminal ECD, mouse CD47 shares 63% and 84% aa sequence identity with human and rat CD47, respectively. A portion of the N-terminal ECD can be shed from smooth muscle cells by MMP-2-mediated proteolysis (4). The ubiquitously expressed CD47 binds to SIRP family members on macrophages, neutrophils, and T cells (5, 6). These interactions prevent macrophage-mediated clearance of healthy CD47-expressing cells and promote immune cell transmigration across the vascular endothelium (5-8). The CD47-SIRPα interaction is species specific, and this lack of cross-species interaction has been implicated in xenotransplantation rejection (16). CD47 associates *in cis* with Fas on T cells and enhances Fas-mediated apoptosis; its ligation promotes T cell energy and dampens Th1 immune responses (9-11). CD47 also associates *in cis* with Integrins α4β1, αVβ3, α2β3, and α2β1 which can positively or negatively modulate Integrin-mediated function (2, 12). In the vasculature, CD47 binding by Thrombospondin-1 inhibits the angiogenic and vasorelaxant effects of nitric oxide (2, 13, 14). On dendritic cells and myeloma cells, CD47 ligation by TSP-1 induces giant cell formation and osteoclast differentiation (15).

References:

1. Sarfati, M. *et al.* (2009) *Curr. Drug Targ.* **9**:842.
2. Isenberg, J.S. *et al.* (2008) *Arterioscler. Thromb. Vasc. Biol.* **28**:615.
3. Lindberg, F.P. *et al.* (1993) *J. Cell Biol.* **123**:485.
4. Maile, L.A. *et al.* (2008) *Mol. Endocrinol.* **22**:1226.
5. Oldenborg, P.-A. *et al.* (2000) *Science* **288**:2051.
6. Liu, Y. *et al.* (2002) *J. Biol. Chem.* **277**:10028.
7. Stefanidakis, M. *et al.* (2008) *Blood* **112**:1280.
8. de Vries, H.E. *et al.* (2002) *J. Immunol.* **168**:5832.
9. Manna, P.P. *et al.* (2005) *J. Biol. Chem.* **280**:29637.
10. Avice, M.-N. *et al.* (2001) *J. Immunol.* **167**:2459.
11. Bouguermouh, S. *et al.* (2008) *J. Immunol.* **180**:8073.
12. Barazi, H.O. *et al.* (2002) *J. Biol. Chem.* **277**:42859.
13. Isenberg, J.S. *et al.* (2009) *Nitric Oxide* **21**:52.
14. Isenberg, J.S. *et al.* (2009) *Matrix Biol.* **28**:110.
15. Kukreja, A. *et al.* (2009) *Blood* **114**:3413.
16. Wang H. *et al.* (2007) *Blood* **109**:836.